46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,325 /  Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

  
7 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04068246
(ClinicalTrials.gov)		August 1, 201921/8/2019The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis PatientsThe AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.Rheumatoid ArthritisDrug: Metformin;Drug: PlaceboSadat City UniversityNULLCompleted18 YearsN/AAll120Phase 1/Phase 2Egypt
2NCT02277574
(ClinicalTrials.gov)		June 201423/7/2014Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid ArthritisA Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid ArthritisRheumatoid ArthritisBiological: AMP-110;Other: PlaceboMedImmune LLCDaiichi Sankyo Co., Ltd.Completed18 Years75 YearsBoth29Phase 1United States
3NCT01878123
(ClinicalTrials.gov)		April 201322/5/2013Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid ArthritisA Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid ArthritisRheumatoid ArthritisBiological: AMP-110;Other: PlaceboMedImmune LLCDaiichi Sankyo Co., Ltd.;Daiichi Sankyo Co., Ltd.Completed18 Years75 YearsBoth26Phase 1United States
4NCT01851278
(ClinicalTrials.gov)		April 201312/4/2013Effectiveness Intraarticular CorticosteroidEffectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to DoseRheumatoid ArthritisDrug: Triamcinolone hexacetonideFederal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloRecruiting18 Years65 YearsBoth60N/ABrazil
5NCT01151644
(ClinicalTrials.gov)		April 201025/6/2010Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic DiseasesSafety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic DiseasesRheumatoid Arthritis;Spondyloarthritis;Systemic Lupus Erythematosus (SLE);Dermatomyositis (DM);DMixed Connective Tissue Disease;Systemic Vasculitis;Systemic Sclerosis (SSc);Sjögren's Syndrome;Antiphospholipid Syndrome;Juvenile Idiopathic Arthritis;Juvenile SLE;Juvenile DMBiological: Anti-pandemic H1N1 influenza vaccineUniversity of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloActive, not recruitingN/AN/ABoth5000Phase 4Brazil
6NCT00239382
(ClinicalTrials.gov)		July 1, 200413/10/2005A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid ArthritisA Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules Once Daily and Meloxicam 15 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With RA.Arthritis, RheumatoidDrug: Meloxicam ampoule;Drug: Meloxicam tabletBoehringer IngelheimNULLCompleted18 YearsN/AAll150Phase 3China
7NCT02184052
(ClinicalTrials.gov)		July 20033/7/2014Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory ConditionsMeloxicam (MOBIC®) Ampoule Post Marketing Surveillance StudyArthritis, RheumatoidDrug: MeloxicamBoehringer IngelheimNULLCompletedN/AN/ABoth121N/ANULL

Back to top